Methylene blue has FDA approval for the treatment of methemoglobinemia, a condition when Fe2+ of hemoglobin gets oxidized to Fe3+, reducing the oxygen-carrying capacity of hemoglobin, and typically presents with cyanosis of the lips and extremities, characteristic "chocolate-colored urine," and hypoxia.Mycoplasma leprae and Pneumocystis jirovecii prophylaxis, benzocaine (a local anesthetic), high altitude water sources, and nitrites such as nitroglycerin or amyl nitrite used for treating coronary artery disease.

The remaining indications are non-FDA approved. The first indication is for vasoplegic syndrome, a type of distributive shock that occurs during coronary procedures (specifically coronary artery bypass grafting) as a means to increase systemic vascular resistance when the use of epinephrine is refractory.Plasmodium falciparum in areas that have shown resistance to chloroquine and pyrimethamine-sulfadoxine.